Cisatracurium

The Basics

What is Cisatracurium?

A nondepolarizing skeletal muscle relaxant for intravenous administration.

Brand names for Cisatracurium

Nimbex

How Cisatracurium is classified

Muscle Relaxants, Neuromuscular Nondepolarizing Agents

Cisatracurium During Pregnancy

Cisatracurium pregnancy category

Category N/ANote that the FDA has deprecated the use of pregnancy categories, so for some medications, this information isn’t available. We still think it’s useful to list historical info, however, given what a common proxy this has been in the past.

What we know about taking Cisatracurium while pregnant

There are no adequate and well-controlled studies of NIMBEX in pregnant women. Animal studies conducted in rats administered cisatracurium besylate during organogenesis found no evidence of fetal harm at 0.8 times (ventilated rats) the exposure from a human starting IV bolus dose of 0.2 mg/kg. The background risk for major birth defects and miscarriage in the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Clinical Considerations Labor or Delivery The action of neuromuscular blocking agents may be enhanced by magnesium salts administered for the management of preeclampsia or eclampsia of pregnancy. Data Animal Data Two embryofetal developmental reproductive toxicity studies were conducted in rats. In a nonventilated rat study, pregnant animals were treated with cisatracurium besylate subcutaneously twice per day from Gestational Day 6 to 15 using subparalyzing doses (2 and 4 mg/kg daily; equivalent to 6- and 12-times, respectively, the AUC exposure in humans following a bolus dose of 0.2 mg/kg IV). In the ventilated rat study, pregnant animals were treated with cisatracurium besylate intravenously once a day between Gestational Day 6 to 15 using paralyzing doses (0.5 and 1 mg/kg; equivalent to 0.4- and 0.8-times, respectively, the exposure in humans following a bolus dose of 0.2 mg/kg IV based on mg/m2 comparison). Neither of these studies revealed maternal or fetal toxicity or teratogenic effects.

Taking Cisatracurium While Breastfeeding

What are recommendations for lactation if you're taking Cisatracurium?

No information is available on the use of cisatracurium during breastfeeding. Because it is short acting, highly polar and poorly absorbed orally, it is not likely to reach the breastmilk in high concentration or to reach the bloodstream of the infant.[1][2] When a combination of anesthetic agents is used for a procedure, follow the recommendations for the most problematic medication used during the procedure.

Maternal / infant drug levels

No information is available on the use of cisatracurium during breastfeeding. Because it is short acting, highly polar and poorly absorbed orally, it is not likely to reach the breastmilk in high concentration or to reach the bloodstream of the infant.[1][2] When a combination of anesthetic agents is used for a procedure, follow the recommendations for the most problematic medication used during the procedure.

Possible effects of Cisatracurium on milk supply

Relevant published information was not found as of the revision date.

Possible alternatives to Cisatracurium

Atracurium, Rocuronium.